TGFB1 and schwannoma: This deposition may be due to activation of pro‐fibrotic signaling pathways that lead to collagen production in both schwannoma cells and activated fibroblasts, representing potential therapeutic targets for therapies such as anti‐TGF‐b antibodies (Fresolimumab) or collagen‐targeting nanoparticles for phothermal therapy.